Alzamend Neuro公司宣布，其候选药物AL001（即“脑内锂”研究）在位于马萨诸塞州总医院进行的II期临床试验中，获得了令人鼓舞的药效学数据。这些积极结果标志着公司在开发新型锂疗法用于治疗神经精神疾病方面取得了重要进展。
Alzamend Neuro公司宣布，其候选药物AL001（即“脑内锂”研究）在位于马萨诸塞州总医院进行的II期临床试验中，获得了令人鼓舞的药效学数据。这些积极结果标志着公司在开发新型锂疗法用于治疗神经精神疾病方面取得了重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.